Cargando…

Identification of a novel miR‐21‐3p/TGF‐β signaling‐driven immune escape via the MHC class I/biglycan axis in tumor cells

Detalles Bibliográficos
Autores principales:	Subbarayan, Karthikeyan, Massa, Chiara, Lazaridou, Maria‐Filothei, Ulagappan, Kamatchi, Seliger, Barbara
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2021
Materias:	Letter to Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7989704/ https://www.ncbi.nlm.nih.gov/pubmed/33783999 http://dx.doi.org/10.1002/ctm2.306

Ejemplares similares

Immune Interaction Map of Human SARS-CoV-2 Target Genes: Implications for Therapeutic Avenues
por: Subbarayan, Karthikeyan, et al.
Publicado: (2021)

Biglycan as a potential regulator of tumorgenicity and immunogenicity in K-RAS-transformed cells
por: Subbarayan, Karthikeyan, et al.
Publicado: (2022)

Biglycan as a mediator of proinflammatory response and target for MDS and sAML therapy
por: Vaxevanis, Christoforos K., et al.
Publicado: (2022)

Identification of microRNAs Targeting the Transporter Associated with Antigen Processing TAP1 in Melanoma
por: Lazaridou, Maria-Filothei, et al.
Publicado: (2020)

Correlation of the tumor escape phenotype with loss of PRELP expression in melanoma
por: Schäfer, Helene, et al.
Publicado: (2023)

Influence of oxygen deficiency and the role of specific amino acids in cryopreservation of garlic shoot tips
por: Subbarayan, Karthikeyan, et al.
Publicado: (2015)

Distinct Molecular Mechanisms of Altered HLA Class II Expression in Malignant Melanoma
por: Meyer, Stefanie, et al.
Publicado: (2021)

Immune Therapy Resistance and Immune Escape of Tumors
por: Seliger, Barbara, et al.
Publicado: (2021)

Interferons and Resistance Mechanisms in Tumors and Pathogen-Driven Diseases—Focus on the Major Histocompatibility Complex (MHC) Antigen Processing Pathway
por: Massa, Chiara, et al.
Publicado: (2023)

Identification of miR-200a-5p targeting the peptide transporter TAP1 and its association with the clinical outcome of melanoma patients
por: Lazaridou, Maria-Filothei, et al.
Publicado: (2020)

The Dark Side of Dendritic Cells: Development and Exploitation of Tolerogenic Activity That Favor Tumor Outgrowth and Immune Escape
por: Seliger, Barbara, et al.
Publicado: (2013)

The Role of Decorin and Biglycan Signaling in Tumorigenesis
por: Diehl, Valentina, et al.
Publicado: (2021)

Biglycan regulates bone development and regeneration
por: Shainer, Reut, et al.
Publicado: (2023)

Breast cancer dataset with biomarker Biglycan
por: Silva Neto, Pedro Clarindo da, et al.
Publicado: (2023)

Dynamically Driven Allostery in MHC Proteins: Peptide-Dependent Tuning of Class I MHC Global Flexibility
por: Ayres, Cory M., et al.
Publicado: (2019)

Malaria-driven adaptation of MHC class I in wild bonobo populations
por: Wroblewski, Emily E., et al.
Publicado: (2023)

Expression and the Prognostic Value of Biglycan in Gastric Cancer
por: Hu, Sizhe, et al.
Publicado: (2022)

Immune Escape Mechanisms and Their Clinical Relevance in Head and Neck Squamous Cell Carcinoma
por: Seliger, Barbara, et al.
Publicado: (2020)

Neuronal MHC Class I Expression Is Regulated by Activity Driven Calcium Signaling
por: Lv, Dan, et al.
Publicado: (2015)

Biglycan: A Multivalent Proteoglycan Providing Structure and Signals
por: Nastase, Madalina V., et al.
Publicado: (2012)

Biglycan expression and its function in human ligamentum flavum
por: Salimi, Hamidullah, et al.
Publicado: (2021)

Mutational Escape in HIV-1 CTL Epitopes Leads to Increased Binding to Inhibitory Myelomonocytic MHC Class I Receptors
por: Yang, Yue, et al.
Publicado: (2010)

COVID-19 Pandemic: Escape of Pathogenic Variants and MHC Evolution
por: Pontarotti, Pierre, et al.
Publicado: (2022)

MHC class I multimers
por: Sun, Mei-Yi, et al.
Publicado: (2001)

IL-2 enhanced MHC class I expression in papillary thyroid cancer with Hashimoto's thyroiditis overcomes immune escape in vitro
por: Hu, Jia-Qian, et al.
Publicado: (2020)

Structural Properties of MHC Class II Ligands, Implications for the Prediction of MHC Class II Epitopes
por: Jørgensen, Kasper Winther, et al.
Publicado: (2010)

Soluble biglycan: a potential mediator of cartilage degradation in osteoarthritis
por: Barreto, Goncalo, et al.
Publicado: (2015)

Decorin knockdown is beneficial for aged tendons in the presence of biglycan expression
por: Beach, Zakary M., et al.
Publicado: (2022)

Biglycan- and Sphingosine Kinase-1 Signaling Crosstalk Regulates the Synthesis of Macrophage Chemoattractants
por: Hsieh, Louise Tzung-Harn, et al.
Publicado: (2017)

The HHV-6A Proteins U20 and U21 Target NKG2D Ligands to Escape Immune Recognition
por: Chaouat, Abigael Eva, et al.
Publicado: (2021)

Biglycan Intensifies ALK5–Smad2/3 Signaling by TGF‐β(1) and Downregulates Syndecan‐4 in Cultured Vascular Endothelial Cells
por: Hara, Takato, et al.
Publicado: (2017)

Ligation of MHC Class II Induces PKC-Dependent Clathrin-Mediated Endocytosis of MHC Class II
por: Masaki, Kento, et al.
Publicado: (2020)

Escape from the Phagosome: The Explanation for MHC-I Processing of Mycobacterial Antigens?
por: Harriff, Melanie J., et al.
Publicado: (2012)

Superantigen and class II MHC molecules.
por: Kim, J.
Publicado: (1995)

Organizing MHC Class II Presentation
por: Fooksman, David R.
Publicado: (2014)

MHC Class II Presentation in Autoimmunity
por: Ishina, Irina A., et al.
Publicado: (2023)

Biglycan enhances gastric cancer invasion by activating FAK signaling pathway
por: Hu, Lei, et al.
Publicado: (2014)

Biglycan fragmentation in pathologies associated with extracellular matrix remodeling by matrix metalloproteinases
por: Genovese, Federica, et al.
Publicado: (2013)

Inhibitory Role of the Small Leucine-Rich Proteoglycan Biglycan in Bladder Cancer
por: Niedworok, Christian, et al.
Publicado: (2013)

Identification of the effector domain of biglycan that facilitates BMP-2 osteogenic function
por: Jongwattanapisan, Prapaporn, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_qem3lhca7s52jqh1taqdmi1p4o